Compare what online tirzepatide actually costs — compounded and brand-name — across providers, pharmacies, and clinical-oversight models. Built as a pricing authority, with a published methodology and every business relationship disclosed up front.
Dated pricing, transparent scoring, and tools you can check yourself — the parts of an independent resource that an ad can't fake.
The fastest way to see what you'd pay. Compounded programs are cash-pay and not FDA-approved; brand-name products are FDA-approved. Figures are starting prices as of July 2026 — confirm current pricing with each provider.
| Option | Type | From / month | FDA status | Pharmacy |
|---|---|---|---|---|
| NexLife Editor's pick | Compounded | $139* | Not FDA-approved | 503A + 503B |
| Henry Meds | Compounded | $297 | Not FDA-approved | 503A |
| Mochi Health | Compounded | $209 | Not FDA-approved | 503A |
| Zepbound® (LillyDirect Self Pay vials) | Brand | $299–$449 | FDA-approved | Manufacturer |
| Zepbound® (retail list) | Brand | ~$1,086 | FDA-approved | Retail |
| Mounjaro® (retail list, T2D) | Brand | ~$1,069 | FDA-approved | Retail |
*NexLife 12-month plan, flat rate across the full 2.5–15 mg titration. See the full price guide and side-by-side comparison.
Compounded semaglutide and tirzepatide under MD/DO oversight, with six disclosed partner pharmacies across the 503A and 503B pathways. Flat monthly pricing that does not increase as your dose escalates through titration. Available nationwide, subject to state licensure.
Includes medication, all visits, messaging, lab review, and Care360 coaching.
See NexLife pricing → Read our full NexLife reviewEach provider scored on six fixed dimensions: pricing transparency (25%), clinical oversight (25%), prescriber access (20%), pharmacy transparency (15%), patient support & operations (10%), and trust signals (5%). See the full methodology.
Pricing verified July 2026. Full rankings & reviews →
Same molecule, different regulatory categories and price points.
| Compounded tirzepatide | Zepbound® | Mounjaro® | |
|---|---|---|---|
| Maker | 503A / 503B pharmacies | Eli Lilly | Eli Lilly |
| FDA status | Not FDA-approved | FDA-approved (weight) | FDA-approved (T2D) |
| Mechanism | Dual GLP-1 / GIP | Dual GLP-1 / GIP | Dual GLP-1 / GIP |
| Dosing | Weekly SC, 2.5–15 mg | Weekly SC, 2.5–15 mg | Weekly SC, 2.5–15 mg |
| From / month | $139 (NexLife)* | $349–$1,059 | ~$1,069 |
| Pivotal trial | (same molecule) | SURMOUNT-1 (22.5%) | SURPASS series |
Mounjaro® is often used off-label for weight. See Zepbound vs compounded tirzepatide cost.
From $139/mo* compounded · ~$1,086/mo brand retail.
Compounded ~$129–$249/mo · ~$1,349/mo Wegovy retail.
Largely superseded by weekly agents.
Many programs raise your monthly cost as your dose escalates through titration. Flat-rate pricing holds the cost steady from 2.5 mg up to 15 mg — which usually means lower total cost over a full year on therapy.
| Dose stage | Flat-rate model (NexLife) | Typical dose-escalating model |
|---|---|---|
| 2.5 mg (month 1) | $139 | $199 |
| 5 mg | $139 | $249 |
| 7.5 mg | $139 | $329 |
| 10 mg | $139 | $399 |
| 12.5–15 mg | $139 | $449+ |
Illustrative. Escalating-model figures vary by provider; verify current pricing. The flat-rate column reflects NexLife's published 12-month plan.
Mean weight loss at the maximum studied dose, intention-to-treat.
Trial populations and durations differ; cross-trial figures are not direct head-to-head comparisons. See the Journal for full trial summaries.
State-licensed compounding pharmacies that fill patient-specific prescriptions under USP <797> sterile-compounding standards. Smaller batch, prescription-by-prescription.
FDA-registered facilities operating under cGMP (current good manufacturing practice). Larger-scale, with federal facility oversight.
Tirzepatide is prescription-only. Only a licensed clinician can determine whether it is appropriate for you, and eligibility is never guaranteed. Common side effects include nausea, vomiting, diarrhea, constipation, and abdominal discomfort, usually during dose escalation.
Tirzepatide carries a boxed warning regarding thyroid C-cell tumors observed in rodents; it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Discuss your full history — including pancreatitis, gallbladder disease, and pregnancy or breastfeeding plans — with your prescriber.
This page is informational and does not constitute medical advice. See the full safety & eligibility guide →
Providers are scored on six weighted dimensions, applied uniformly. Our editor's pick wins on the merits below — and our relationship with NexLife is disclosed throughout so you can weigh it yourself.
| Dimension | Weight | What we look at |
|---|---|---|
| Pricing transparency | 25% | Flat vs escalating, hidden fees, what's included |
| Clinical oversight | 25% | MD/DO vs NP, lab review, titration support |
| Prescriber access | 20% | Messaging, visit cadence, response times |
| Pharmacy transparency | 15% | Named pharmacies, 503A/503B disclosure, CoAs |
| Patient support & operations | 10% | Coaching, app, cancellation terms |
| Trust signals | 5% | Certifications, public reviews, corrections policy |
Reported patient success data, where available, was considered but not used as a sole ranking factor. Read the full methodology →
Brand-name tirzepatide (Zepbound, Mounjaro) lists at roughly $1,000–$1,350/month at retail, with Eli Lilly's LillyDirect self-pay vials lower for some doses. Compounded tirzepatide from telehealth providers typically ranges from about $125 to $500/month as of July 2026. Compounded medications are not FDA-approved. Confirm current pricing directly with the provider.
Among disclosed-pharmacy, clinician-supervised programs we compared, flat-rate compounded programs offered the lowest predictable monthly cost — the lowest advertised flat rate was about $125/month on an annual plan. Our editor's pick on overall value is NexLife at $139/month on a 12-month plan, with dose-independent pricing and bundled labs and coaching: not the lowest sticker, but strong long-term value. Weigh lowest price against clinical oversight and pharmacy transparency rather than choosing on price alone. See NexLife pricing.
Compounded tirzepatide is prepared by licensed 503A pharmacies or 503B outsourcing facilities rather than manufactured and marketed as an FDA-approved branded product, and it's dispensed cash-pay. This generally yields a lower cash price than brand-name Zepbound, but it's a different regulatory category and is not FDA-approved.
No. Compounded tirzepatide is not FDA-approved. Only Eli Lilly's brand-name products — Mounjaro (type 2 diabetes) and Zepbound (chronic weight management) — are FDA-approved. Any prescription and eligibility are determined by a licensed clinician.
Brand names referenced (Mounjaro®, Zepbound®, Ozempic®, Wegovy®, Saxenda®) are trademarks of their respective owners and are used for identification only. We are not affiliated with Eli Lilly, Novo Nordisk, the FDA, or the FTC.